The Report Insomnia Therapeutics Market
Analysis By Treatment Type [Devices, Drugs (Benzodiazepines,
Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin
Antagonists)], By Sales Channel, And Segment Forecasts, 2018 – 2025
The global insomnia therapeutics
market is expected to reach USD 3.45 billion by 2025, according to a new
report by Grand View Research, Inc. The market is primarily driven by the
presence of patented molecules, potential clinical pipeline candidates, rising
stress level, and increase in geriatric population who find it difficult to
fall asleep. Increase in prevalence of insomnia & awareness about this
condition and availability of safer drugs are anticipated to fuel revenue
growth.
Insomnia
is estimated to affect approximately 35% of the global population. Different
patterns of the condition include difficulty in sleep initiation and
maintenance, which is generally accompanied with frequent awakenings &
awakening too early with trouble sleeping again. Long-term insomnia can hamper
everyday life, which may result in nonproductive work hours. If left untreated,
this condition may lead to severe depression and nervous breakdown of the
patient.
Factors
influencing insomnia therapeutics market growth include rising stress level,
presence of patented molecules in the market, potential drugs in clinical
pipeline, introduction of technologically advanced medical devices, and growing
geriatric population. Growing awareness about the impact of sleep deprivation
on everyday life is anticipated to increase adoption rate of various treatments
for insomnia, which is expected to lead to revenue growth of the insomnia
therapeutics market.
Currently,
widely adopted treatment options for insomnia include generic
nonbenzodiazepines and antidepressants even though other novel agents such as
orexin antagonists and melatonin antagonists are available in the market.
Launch of Eisai’s Lemborexant is expected to cater to unmet medical needs in
this segment and fuel growth of this market over the forecast period. According
to United Nations (UN) report in 2015, population in the age group of 60 years
and above is projected to grow by 56% and is expected to reach around 1.4
billion by 2030. These statistics indicate the growing geriatric population.
Since this population base is more susceptible to sleep deprivation, the demand
for insomnia therapeutics is anticipated to increase.
Access Research Report of Insomnia Therapeutics Market @ www.grandviewresearch.com/industry-analysis/insomnia-therapeutics-market
Further Key Findings
From the Report Suggest:
· North America held majority of the share in 2016 due to
increase inawareness about diseases, growing geriatricpopulation, and high
adoption of therapeutics for treatment.
· The U.S. dominated North America owing to the presence of
largest sleep-deprived population and use of patented drugs for treatment.
· Japan is the second largest market after the U.S. Asia
Pacific is expected to be the fastest growingmarket due to the presence
ofemerging economies like China & India and launch of new drugs.
· Some of the key players are Takeda Pharmaceutical Co.
Ltd.; Vanda Pharmaceuticals; Merck & Co, Inc.;Pfizer Inc.; Teva
Pharmaceutical Industries Ltd.; Mylan N. V.; Sumitomo Dainippon Pharma Co.,
Ltd.; Sanofi; Paratek Pharmaceuticals;and Ebb Therapeutics.
Grand View Research has segmented the insomnia
therapeutics market on the basis of treatment type, sales channel, and region:
Insomnia Therapeutics
Market Treatment Type Outlook (Revenue, USD Million, 2014 - 2025)
·
Drugs
o Benzodiazepines
o Nonbenzodiazepines
o Antidepressants
o Orexin
antagonist
o Melatonin
antagonist
o Others
·
Devices
Insomnia Therapeutics
Market Sales Channel Outlook (Revenue, USD Million, 2014 - 2025)
·
Prescription
·
Over-the-Counter(OTC)
Insomnia Therapeutics
Market Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o Japan
o China
·
Latin America
o Brazil
o Mexico
·
Middle East & Africa
o South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment